European Medicines Agency asked to approve AstraZeneca-Oxford vaccine
Jan 14 2021
The HSE will remain mainly reliant on Pfizer BioNTech which has promised 40,000 doses a week to Ireland until the end of February.
The Sydney Morning Herald reports The Australian and New Zealand Society for Immunology (ASI) point to a recent study, which found the AstraZeneca vaccine to be 62% effective in preventing someone from contracting COVID-19.
Chief Medical Officer Professor Paul Kelly said the current Novavax Phase Three trial involving 30,000 participants in the United States was showing a "very strong performance" much "quicker" than expected.
"The question is really whether it (AstraZeneca) is able to provide herd immunity".
"I have a very strong feeling that Novavax, or one of the other protein vaccines will be the long-term option for vaccination for the world", Prof Kelly said.
Australia's chief medical officer, Paul Kelly, attempted to address concerns around the efficacy of the AstraZeneca vaccine, calling it "effective", "safe" and "high quality".
"So that would be another option later in the year for us, hopefully".
He told LBC Radio: "We have all got older loved ones and if we want to protect as many as we can as quickly as possible, with a meaningful amount of protection, then the right strategy for us is to give the initial first dose and come back for the second when we have given more people the initial first dose", he said.
He also said that they will borrow an additional P1 billion to ensure that each resident will receive a free COVID-19 vaccine.
The European Union and EMA are under pressure to speed up approval of new vaccines against the virus, which has already claimed more than 620,000 lives across the continent. "In one group, it was 90 per cent". Besides, the vaccine was approved for use in Belarus. "Our choice is whether to offer everything we have now to protect as many people as we can, or to leave some effective vaccines in the warehouse".
The truth is, the first of those has already been administered in Spain since the starting of the month and it's anticipated that in the coming weeks the variety of doses that arrive in the nation and the charge of vaccination to well being staff and the aged, that are the teams riskier.